- Results from long-term study showed patients who received Zimmer Biomet Holdings' (NYSE:ZBH) Mobi-C Cervical Disc in a cervical total disc replacement (cTDR) procedure experienced sustained treatment benefits over the traditional method. The data were just published in the International Journal of Spine Surgery.
- Researchers found that patients who received the Mobi-C had lower pain scores, maintained range of motion, had less adjacent level degeneration and less adjacent level subsequent surgery and a lower rate of secondary surgery compared to anterior cervical discectomy and fusion (ACDF) (removing all or part of the damaged disc and fusing the vertebrae together to stabilize the area).
- GM Spine Division Joe Ross says, "This study further validates the strengths of Mobi-C as a solution for cervical total disc replacement. The positive clinical outcomes remain consistent with previous findings, mainly that Mobi-C continues to deliver positive patient outcomes including efficacy, safety, patient satisfaction and fewer follow-up surgeries. It is particularly important that the clinical effectiveness of cTDR versus ACDF becomes more apparent when treatment increases from one to two levels, indicating a significant benefit for Mobi-C in two-level procedures, which affects an estimated one in three cervical disc patients."
- Now read: Daily Insider Ratings Round Up 2/20/18: BH, DM, LGCY, LJPC, MCHX, SNAP, ZBH
Original article